Insperity price target lowered to $34 from $51 at JPMorgan

JPMorgan analyst Andrew Polkowitz lowered the firm’s price target on Insperity (NSP) to $34 from $51 and keeps an Underweight rating on the shares. The company missed its guidance for the third consecutive quarter and lowered its 2025 adjusted EBITDA and earnings outlooks, primarily due to higher than anticipated health care cost trends, the analyst tells investors in a research note. The firm believes Insperity must restore investor confidence that it can manage benefits cost risk within its model.